Agilex Biolabs
Adelaide, Australia· Est.
Australia's leading CRO delivering fast, cost‑effective bioanalysis for drug development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australia's leading CRO delivering fast, cost‑effective bioanalysis for drug development.
OncologyNeurologyInfectious DiseaseMetabolic DisordersImmunologyDermatology
Technology Platform
Core capabilities include LC‑MS/MS for small‑molecule quantification, validated immunoassays (ELISA, MSD, Gyrolab) for biologics, flow cytometry for cellular phenotyping, and PCR‑based biomarker assays, all operated under GLP/GCP compliance.
Opportunities
Expanding the Australian clinical‑trial rebate program and increasing demand for integrated non‑clinical/clinical bioanalysis present strong growth avenues.
Risk Factors
Regulatory scrutiny, competition from larger global CROs, and dependence on pharma sponsors could impact market share.
Competitive Landscape
Agilex differentiates itself through a single‑roof data generation model and rapid turnaround, competing with global CROs such as Charles River, Labcorp Drug Development, and Covance.